Prosecution Insights
Prosecution Insights
13 pending office actions • 9 art units • 12 examiners • 0 of 13 (0%) have an AI response strategy ready • 20 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (15%) |
| §103 only | 1 (8%) |
| §112 only | 3 (23%) |
| Double-patenting + other | 1 (8%) |
| Multi-statute (no §101) | 6 (46%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CARTER, SANDRA DILLAHUNT | 2 | 56.1% | +29.7% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 30.0% | +38.8% |
| SANG, HONG | 1 | 54.7% | +62.6% |
| STAVROU, CONSTANTINA E | 1 | 44.2% | +36.3% |
| DUFFY, BRADLEY | 1 | 54.6% | +45.5% |
| ZAIDI, SYED A | 1 | 81.8% | +12.4% |
| WILLIAMS, KEITH RICHARD | 1 | 41.7% | +0.0% |
| BERKE-SCHLESSEL, DAVID W | 1 | 66.6% | +31.9% |
| BENAVIDES, JENNIFER ANN | 1 | 51.3% | +48.6% |
| ANDERSON-FEARS, KEENAN NEIL | 1 | 9.1% | +45.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19211886 | CONTENT AUTHENTICATION AND VALIDATION VIA MULTI-FACTOR DIGITAL TOKENS, SYSTEMS, AND METHODS | ZAIDI, SYED A | 23d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16985090 | Artificial Target Cells for in-vitro CAR Cytotoxicity and ADCC validation | DHAR, MATASHA | 743d overdue |
| 18225098 | COMPUTING AFFINITY FOR PROTEIN-PROTEIN INTERACTION | ANDERSON-FEARS, KEENAN NEIL | 22d overdue |
| 19277274 | COMPOSITIONS AND METHODS RELATED TO POTENT CYTOTOXIC M-CENK CELLS FROM CD3/CD14-DEPLETED APHERESIS PRODUCTS | DUFFY, BRADLEY | 12d |
| 19399287 | NK-92 Cells with Cytokine Induced Memory-Like Cytotoxicity And Derivatives Thereof | SANG, HONG | — |
| 19357552 | DUAL-SPECIFIC BINDING MOLECULE USEFUL FOR ISOLATING SPECIFIC BLOOD CELLS | STAVROU, CONSTANTINA E | — |
| 18775316 | TUMORICIDAL AND ANTIMICROBIAL COMPOSITIONS AND METHODS | BERKE-SCHLESSEL, DAVID W | — |
| 18278797 | Highly Potent M-CENK Cells And Methods | BENAVIDES, JENNIFER ANN | — |
| 16576415 | SAMPLE DESTRUCTION VALIDATION SYSTEM AND METHODS | FONTAINHAS, AURORA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18225098 | COMPUTING AFFINITY FOR PROTEIN-PROTEIN INTERACTION | ANDERSON-FEARS, KEENAN NEIL | 22d overdue |
| 19277274 | COMPOSITIONS AND METHODS RELATED TO POTENT CYTOTOXIC M-CENK CELLS FROM CD3/CD14-DEPLETED APHERESIS PRODUCTS | DUFFY, BRADLEY | 12d |
| 19211886 | CONTENT AUTHENTICATION AND VALIDATION VIA MULTI-FACTOR DIGITAL TOKENS, SYSTEMS, AND METHODS | ZAIDI, SYED A | 23d |
| 19407885 | Interleukin-15, PD-1 Antibodies, and Taxanes in Non-Small Cell Lung Cancer | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 19399287 | NK-92 Cells with Cytokine Induced Memory-Like Cytotoxicity And Derivatives Thereof | SANG, HONG | — |
| 19357552 | DUAL-SPECIFIC BINDING MOLECULE USEFUL FOR ISOLATING SPECIFIC BLOOD CELLS | STAVROU, CONSTANTINA E | — |
| 18775316 | TUMORICIDAL AND ANTIMICROBIAL COMPOSITIONS AND METHODS | BERKE-SCHLESSEL, DAVID W | — |
| 18497169 | MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF | CARTER, SANDRA DILLAHUNT | — |
| Art Unit | Apps |
|---|---|
| 1632 | 2 |
| 1675 | 2 |
| 1658 | 1 |
| 1646 | 1 |
| 1643 | 1 |
| 2432 | 1 |
| 1663 | 1 |
| 1651 | 1 |
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19407885 | Interleukin-15, PD-1 Antibodies, and Taxanes in Non-Small Cell Lung Cancer | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103DP | Final Rejection | — | Pending | Dec 03, 2025 |
| 19399287 | NK-92 Cells with Cytokine Induced Memory-Like Cytotoxicity And Derivatives Thereof | SANG, HONG | 1646 | §102§112 | Final Rejection | — | Pending | Nov 24, 2025 |
| 19357552 | DUAL-SPECIFIC BINDING MOLECULE USEFUL FOR ISOLATING SPECIFIC BLOOD CELLS | STAVROU, CONSTANTINA E | 1632 | §102§103 | Non-Final OA | — | Pending | Oct 14, 2025 |
| 19277274 | COMPOSITIONS AND METHODS RELATED TO POTENT CYTOTOXIC M-CENK CELLS FROM CD3/CD14-DEPLETED APHERESIS PRODUCTS | DUFFY, BRADLEY | 1643 | §103§112 | Final Rejection | 12d | Pending | Jul 22, 2025 |
| 19211886 | CONTENT AUTHENTICATION AND VALIDATION VIA MULTI-FACTOR DIGITAL TOKENS, SYSTEMS, AND METHODS | ZAIDI, SYED A | 2432 | §103 | Final Rejection | 23d | Pending | May 19, 2025 |
| 18897262 | Methods And Systems For Producing A Protein Of Interest In A Plant | WILLIAMS, KEITH RICHARD | 1663 | §112 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18775316 | TUMORICIDAL AND ANTIMICROBIAL COMPOSITIONS AND METHODS | BERKE-SCHLESSEL, DAVID W | 1651 | §102§103 | Non-Final OA | — | Pending | Jul 17, 2024 |
| 18497169 | MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF | CARTER, SANDRA DILLAHUNT | — | §112 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18497163 | MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF | CARTER, SANDRA DILLAHUNT | — | §112 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18278797 | Highly Potent M-CENK Cells And Methods | BENAVIDES, JENNIFER ANN | 1675 | §103§112 | Non-Final OA | — | Pending | Aug 24, 2023 |
| 18225098 | COMPUTING AFFINITY FOR PROTEIN-PROTEIN INTERACTION | ANDERSON-FEARS, KEENAN NEIL | 1687 | §101§103 | Final Rejection | 22d overdue | Pending | Jul 21, 2023 |
| 16985090 | Artificial Target Cells for in-vitro CAR Cytotoxicity and ADCC validation | DHAR, MATASHA | 1632 | §103§112 | Non-Final OA | 743d overdue | Pending | Aug 04, 2020 |
| 16576415 | SAMPLE DESTRUCTION VALIDATION SYSTEM AND METHODS | FONTAINHAS, AURORA M | 1675 | §101§112 | Non-Final OA | — | Pending | Sep 19, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial